Remove Bioavailability Remove Drug Delivery Remove Life Science
article thumbnail

Vevye: A New Cyclosporine Solution for Dry Eye Disease

XTalks

Furthermore, the bioavailability of the active pharmaceutical ingredient (API) into the cornea is up to four times stronger with EyeSol technology. Attendees will understand best practices for novel drug delivery design and development. What Is Dry Eye Disease?

article thumbnail

Considerations for Neuroscience Trials with Intrathecal Delivery and Other Methods of Direct CNS Administration

XTalks

One of the biggest challenges with developing therapies to treat CNS disorders is the delivery of systemically administered investigational products (IPs) to the brain, which is limited by the blood-brain barrier. Some methods of direct CNS administration include intrathecal, intraparenchymal and intracerebroventricular (ICV) delivery.

Trials 83
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

XPhyto Announces Drug Formulation Strategy and 2021 Milestones Innovation to Impact

The Pharma Data

CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT ) (“ XPhyto ” or the “ Company “) is pleased to announce its drug formulation and delivery business strategy and milestones for 2021. Vektor will begin planning and development work for the incorporation of various psychedelic compounds into its drug formulations.

Drugs 52
article thumbnail

Gelteq IPO: Supporting Gel Technology for Oral Drug Delivery

XTalks

Gelteq centers its technology on a proprietary, customizable gel platform designed for precise drug delivery, supporting prescription drugs, nutraceuticals, pet care and sports supplements.

article thumbnail

Skin Cancer Awareness Month 2024 and Insights from Medicus Pharma

XTalks

For healthcare and life sciences industries, Skin Cancer Awareness Month helps highlight the importance of preventive measures and early detection. is a biotech and life sciences company dedicated to advancing the clinical development of innovative and groundbreaking therapeutic assets.